RNA
Avidity Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.19
−2.81%Year over year
Reported trailing growth
- Revenue
- +235.3%
- EBITDA
- +49.9%
- EBIT
- +47.0%
- EPS
- -43.8%
- Free cash flow
- +56.8%
- Operating cash flow
- +57.0%
Forward estimates
Based on analyst estimates
- Revenue
- -38.8%
- EBITDA
- +62.1%
- EPS
- -14.2%
Three-year CAGR
- Revenue
- +26.4%
- EBITDA
- +79.7%
- EBIT
- +79.7%
- Net income
- +76.2%
- EPS
- -55.0%
- Free cash flow
- +86.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026